Date: 2017-02-08
Type of information: Financing round
Company: Acticor Biotech (France)
Investors: Cap Decisif Management (France)
Amount: €2,9 million
Funding type: financing round
Planned used: These funds will enable Acticor Biotech to pursue the development of its lead candidate ACT017 in acute ischemic stroke, toward its entry in phase I clinical trial. ACT-017 is a humanized Antibody Fragment (Fab) directed againstplatelet glycoprotein VI (GPVI). Evidence of antithrombotic efficacy of ACT-017 and safety of inhibition of
GPVI have been established both ex vivo and in vivo. The target is involved in the growth of the thrombus, but not in physiological hemostasis. This limits the bleeding risk associated with its inhibition.
In January 2017, the society received a positive feedback from the MHRA (UK Medicine & Healthcare products Regulatory Agency) in London about its pharmaceutical and preclinical package, and secured its first GLP (Good Laboratory Practice) Batch for the Toxicology Package. The first subject could thus be scheduled for early Q4 2017.
Others: * On February 7, 2017, Acticor Biotech, a biotechnology company focused on the treatment of acute ischemic stroke, announced that it has raised €1,5 million from CapDecisif Management. Acticor Biotech had already secured €1,4 million in the first closing, which brings the total amount invested to €2,9 million.
Therapeutic area: Cardiovascular diseases - Cerebrovascular diseases
